Our results indicate that features of physiological and pathogenic autoimmunity against GAD65 converge in T1D, highlighting the importance of performing orthogonal and multilayered analysis of GAD65 responses in clinical trials, as well as including healthy donors as a reference to be able to discriminate physiological responses from disease- and/or treatment- specific ones. Here, GAD2 is linked to type 1 diabetes mellitus.